← Scroll for more →
Argenx SE (ARGX)
Biological Products, (No Diagnostic Substances)
Latest Price
$897.85
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
118.34
P/B Ratio
7.59
Valuation metrics
adjust assumptions →EPS: $19.57
Book value / share: $118.34
Formula: √(22.5 × EPS × BVPS)
Graham Number
$228.27
74% downside
EPS: $19.57
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$293.55
67% downside
Institutional Ownership
45.6% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 5.23M | $4.85B | 8.45% | +240.4K | 2026-06-30 |
| Price T Rowe Associates Inc | 2.68M | $2.48B | 4.33% | -696.9K | 2026-06-30 |
| Jupiter Topco LLC | 2.47M | $2.29B | 4.00% | -- | 2026-06-30 |
| Capital World Investors | 2.20M | $2.04B | 3.55% | -56.4K | 2026-06-30 |
| Artisan Partners Limited Partnership | 1.51M | $1.40B | 2.44% | +40.8K | 2026-06-30 |
| Avoro Capital Advisors LLC | 1.00M | $927.0M | 1.62% | -- | 2026-06-30 |
| Wellington Management Group LLP | 930.5K | $863.0M | 1.50% | -90.9K | 2026-06-30 |
| BlackRock, Inc. | 777.2K | $721.0M | 1.26% | -31.1K | 2026-06-30 |
| Rtw Investments, LP | 709.4K | $658.0M | 1.15% | -- | 2026-06-30 |
| Morgan Stanley | 643.1K | $596.0M | 1.04% | +82.4K | 2026-06-30 |